TY - JOUR
T1 - Pentosidine and increased fracture risk in older adults with type 2 diabetes
AU - Schwartz, Ann V.
AU - Garnero, Patrick
AU - Hillier, Teresa A.
AU - Sellmeyer, Deborah E.
AU - Strotmeyer, Elsa S.
AU - Feingold, Kenneth R.
AU - Resnick, Helaine E.
AU - Tylavsky, Frances A.
AU - Black, Dennis M.
AU - Cummings, Steven R.
AU - Harris, Tamara B.
AU - Bauer, Douglas C.
PY - 2009/7
Y1 - 2009/7
N2 - Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.
AB - Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=67650263891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650263891&partnerID=8YFLogxK
U2 - 10.1210/jc.2008-2498
DO - 10.1210/jc.2008-2498
M3 - Article
C2 - 19383780
AN - SCOPUS:67650263891
SN - 0021-972X
VL - 94
SP - 2380
EP - 2386
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 7
ER -